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ABSTRACT Breast cancer is one of the most frequently diagnosed malignancies during pregnancy. Here, we review the management of women
with breast cancer during pregnancy (BCP), focusing on biology, diagnosis and staging, local and systemic treatments, obstetric
care and long-term follow-up of children with prenatal exposure to anticancer treatments.Breast cancer is one of the most
frequently diagnosed malignancies during pregnancy. Here, we review the management of women with breast cancer during
pregnancy (BCP), focusing on biology, diagnosis and staging, local and systemic treatments, obstetric care, and long-term follow-
up of children with prenatal exposure to anticancer treatments.
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Introduction
Breast cancer represents the most common tumor diagnosed
in  women  and  the  most  frequent  malignancy  in  women  of
reproductive  age1.  Approximately  7%  of  all  breast
carcinomas  are  diagnosed  annually  in  patients  below  40
years,  and  the  incidence  is  even  higher  in  developing
countries2.  The  overall  incidence  of  breast  cancer  during
pregnancy  (BCP)  varies  between  2.4  and  7.3  per  100,000
pregnancies3-8; however, breast cancer is predicted to become
more  common  due  to  the  current  trend  of  postponing
pregnancy to later  in life9  and evidence suggesting that  both
the  incidence  of  breast  cancer  in  young  women  and  the
occurrence of BCP are increasing10,11.
Biology and prognosis
Breast  cancer  arising  at  a  young  age  has  potentially  unique
biologic  features12:  as  shown  by  gene-expression  profiling,
the  complexity  of  this  condition  seems  to  go  beyond  breast
cancer  subtype  distribution13.  The  hormonal  milieu  during
pregnancy  with  its  growth-promoting  effects  might
theoretically  result  in  a  more  aggressive  biology  of  breast
cancer14.  Although  some  studies  have  suggested  no  major
differences  in  the  expression  of  hormone  receptors  and
HER2  between  pregnant  and  non-pregnant  age-matched
breast  cancer  patients15-17,  several  studies  have  shown  that
BCP  seems  to  be  more  commonly  associated  with
unfavorable  tumor  biology  such  as  predominance  of  triple-
negative  breast  carcinomas  (TNBC)18-20,  high  expression  of
potentially  relevant  cancer  targets  (e.g.,  PD1/PDL1,  SRC,
insulin growth factor and Wnt/β-catenin, RANK ligand), and
low prevalence of tumor-infiltrating lymphocytes21-23.
The  unique  biologic  features  of  BCP  and  the  more
frequent delay in diagnosis might explain the poor prognosis
reported by some authors, even if the immediate postpartum
period  showed  a  clear  trend  toward  inferior  outcomes
compared with outcomes during pregnancy or in women
with  non-pregnancy-related  breast  cancer24.  Moreover,
patients  with  BCP  could  be  offered  “nonstandard”  and
potentially suboptimal systemic therapies,  with a possible
negative impact on their prognosis. On the contrary, patients
with BCP treated at a single center who received the same
standard anthracycline-based chemotherapy regimen during
pregnancy had similar clinical outcomes than non-pregnant
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patients with breast cancer16. Similar findings were observed
in the largest cohort study available17.
Diagnosis and staging
BCP generally presents at a more advanced stage at diagnosis
than breast cancer in the general population25,26. The possible
delay  in  diagnosis  is  related  to  the  fact  that  pregnancy
increases  breast  density  and  nodularity,  making  clinical  and
radiologic examinations more difficult27-29. Physicians should
thus  be  aware  that  a  breast  lump in  a  pregnant  patient  may
be associated with a cancer diagnosis; in these cases, imaging
and  biopsies  should  be  performed  without  delay25.
Histopathological  diagnosis  based  on  core  biopsy  represents
the  gold  standard  for  BCP  and  should  follow  standard
procedures  as  in  non-pregnant  patients,  but  the  pathologist
needs to be informed about the pregnancy status to properly
consider  alterations  that  may be caused by the  physiological
modifications of breast tissue during pregnancy11,25.
Imaging procedures for diagnosis and staging should aim
to limit exposure to ionizing radiation11,25. Breast ultrasound
and mammography with abdominal shielding can be safely
and  effectively  performed  in  pregnant  patients30,31  at  all
gestational ages; however, contrast-enhanced breast magnetic
resonance  imaging  (MRI)  is  not  recommended  due  to
inadequate  data  concerning  fetal  safety  with  contrast
media11,25.  Ultrasound  represents  the  preferred  imaging
modality for staging the abdomen and pelvis, and chest X-ray
with  abdominal  shielding  can  be  performed  to  stage  the
chest25. In case of advanced disease or suspected metastasis,
diffusion-weighted whole-body MRI without gadolinium can
be  considered  after  the  first  trimester25.  Computed
tomography, bone scan, and positron emission tomography
should be avoided during pregnancy11,25.
Genetic counseling should be offered to pregnant breast
cancer patients, especially if there is a family history of breast
carcinoma  or  a  TNBC  diagnosis,  similarly  to  what  is
recommended for all young patients with breast cancer32-34.
Local treatment
Surgical management
Surgery can be safely performed at any time during gestation
by making careful risk/benefit assessment because of the need
for anesthesia. The surgical approach should follow the same
guidelines  as  for  non-pregnant  cases11,25.  Mastectomy is  not
mandatory  for  patients  with  BCP  solely  on  the  basis  of
possible  delay  in  the  delivery  of  radiotherapy11,25.  Although
the  available  published  data  on  breast  conservation  are
limited,  they  support  the  safety  and  feasibility  of  this
procedure  in  pregnant  patients35.  However,  patients
diagnosed  in  the  first  trimester  who  desire  to  conserve  the
breast should be informed about a possible increased risk of
local  recurrence  due  to  the  long  delay  in  postoperative
radiotherapy35.
According to the American Society of Clinical Oncology
(ASCO), clinicians should not recommend sentinel lymph
node biopsy (SLNB) in patients with BCP36. However, the
use of  lymphoscintigraphy with technetium-99 SLNB has
been shown to be safe and feasible during pregnancy37-40. The
1-day protocol is associated with a negligible dose to the fetus
(i.e., ≤0.014 mGy), much lower than the limit established by
the  United  States  (US)  National  Council  on  Radiation
Protection and Measurements41. Hence, specific guidelines
for patients with BCP suggest that SLNB rather than axillary
clearance should be offered whenever indicated11,25.
Blue dye for mapping should be discouraged in pregnant
patients  due  to  the  low  but  potentially  harmful  risk  of
anaphylactic reaction11,25  and the capacity of radiolabeled
colloid  alone  to  identify  sentinel  lymph nodes  in  99% of
patients.
For  breast  cancer  patients  who  undergo  mastectomy,
breast reconstruction with an expander is more feasible and
safer than autologous flap-based procedures and should be
offered to all patients except those with inflammatory breast
cancer11,32,42.
Radiotherapy
Exposure  of  the  fetus  to  radiotherapy  can  cause  several
adverse  effects  (e.g.,  intrauterine  growth  restriction,  mental
retardation, risk of childhood cancer, fetal death)25. Although
some  successful  cases  of  radiotherapy  for  BCP  with  the
subsequent birth of healthy children have been reported, the
available data are too limited to draw solid conclusions and it




The indication for using chemotherapy in patients with BCP
should  follow  standard  recommendation  as  in  the  non-
pregnant setting and should be based on both tumor biology
and tumor stage; however, in this setting, some specific issues
should be considered,  including gestational  age at  diagnosis,
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expected  date  of  delivery,  and the  preferences  of  the  patient
and her family11,25.
In patients with BCP, chemotherapy is  contraindicated
during the first trimester of gestation, while it can be safely
administered in the second and third trimesters11,25.
The first trimester is the period of organogenesis, which is
characterized by high vulnerability  to  drugs  and possible
occurrence of spontaneous abortions and major congenital
fetal  malformations11,25.  According  to  the  US  National
Toxicology Program Monograph, the overall rate of major
malformations following exposure to chemotherapy during
the first  trimester  was 14%, with some chemotherapeutic
agents  (i.e.,  cyclophosphamide  and 5-fluorouracil)  being
associated with a higher risk of major malformations (18%
and 31%, respectively)44. Termination of pregnancy is not
associated with improved maternal outcome45; however, for
women with stage IV disease and for those with high-risk
early-stage breast cancer diagnosed during the first trimester,
termination of pregnancy can be considered to avoid delay in
the initiation of cytotoxic therapy. During the second and
third  trimesters,  the  administration  of  chemotherapy  is
associated with an overall 3% rate of major malformations44,
similar to the prevalence in the US general population46,47.
Nonetheless, the use of chemotherapy during the second
and third  trimesters  can  be  associated  with  an  increased
number  of  obstetric  and  fetal  complications,  including
intrauterine growth restriction,  hypertensive disorders  of
pregnancy, and early delivery in approximately 10-20% of
cases11 ,25 .  This  relatively  higher  risk  of  pregnancy
complications  calls  for  a  multidisciplinary  evaluation  of
patients  undergoing  chemotherapy  during  pregnancy,
including careful monitoring of fetal growth and maternal
blood  pressure  (see  also  next  paragraph).  Meanwhile,
iatrogenic prematurity is associated with impaired cognitive
development48 ,49  and  should  be  avoided  whenever
possible11,25.
Anthracycline-based  or  anthracycline/taxane-based
chemotherapy  regimens  are  standard  of  care  for  treating
breast  cancer50,51  and  should  be  recommended  also  in
patients with BCP during the second and third trimesters11,25.
Anthracyclines  are  the  most  studied  chemotherapy
compounds during pregnancy, with more than 400 women
with  BCP  treated  with  these  regimens5 2 .  Hence,
anthracycline-based chemotherapy should be considered as
the first choice11,25. In non-pregnant breast cancer patients,
the  addition  of  5-fluorouracil  to  anthracycline  and
cyclophosphamide has been shown to be associated with no
survival  benefit  but  increased  toxicity53;  therefore,  the
combinat ion  of  doxorubic in  or  ep i rubic in  and
cyclophosphamide (i.e., AC or EC, respectively) should be
considered the preferred option also in women with BCP11,25.
Clinical experience with the use of taxanes in patients with
BCP is more limited. Docetaxel and paclitaxel are substrates
for the placental P-glycoprotein transporter that seems to
reduce the amount of drug passing from the placenta into the
fetus; even in experimental models, paclitaxel and docetaxel
were shown to persist at low levels in fetal tissues for a long
time55. A systematic review of women with BCP, including 50
pregnancies  with  exposure  to  paclitaxel  and  docetaxel,
showed that taxanes were well tolerated during pregnancy
with manageable toxicities56. Thus, when clinically indicated,
the use of taxanes can be considered during pregnancy11,25.
Due to the better toxicity profile and no need for granulocyte
colony-stimulating factors (G-CSF) nor premedication with
high-dose steroids, weekly paclitaxel should be preferred in
women with BCP11,25.
Dose-dense  chemotherapy  is  used  in  high-risk  non-
pregnant patients57,58,  and one small  retrospective cohort
study  evaluated  the  feasibility  of  this  treatment  during
pregnancy59. Although the study showed no increased risk of
fetal or maternal complications, dose-dense chemotherapy
should not be used in women with BCP due to the limited
data available and the need for G-CSF support.
Clinicians should be aware that the pharmacokinetics of
some  cytotoxic  drugs  (e.g.,  doxorubicin,  epirubicin,
docetaxel,  and  paclitaxel)  might  be  altered  during
pregnancy60,61.  Nonetheless,  dose  reduction  as  well  as
increased  doses  and  treatment  intervals  should  be
avoided11,25.
A 3-week interval between the last dose of chemotherapy
and the expected date of delivery should be allowed to avoid
delivery  during the  nadir  period11,25.  Due to  the  possible
occurrence  of  spontaneous  delivery  after  week  34  of
gestation, chemotherapy should be discontinued at week 34
of gestation11,25. Weekly chemotherapy regimens (e.g., weekly
epirubicin  and  weekly  paclitaxel)  have  a  lower  risk  of
hematological toxicity and shorter nadir periods; hence, they
might be considered as a valid treatment option in pregnant
patients,  particularly  as  single-drug  treatment  in  the
metastatic setting11,25.
Anti-HER2 agents
Trastuzumab  is  approved  for  the  treatment  of  patients  with
HER2-positive  breast  cancer  in  the  neoadjuvant,  adjuvant,
and  metastatic  settings.  However,  the  HER2  pathway  has  a
crucial role in fetal organogenesis and is also involved in the
early  conception  and  implantation  phases62.
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Immunoglobulin G antibodies can cross the placenta starting
from  the  second  trimester  of  pregnancy,  with  a  continued
increase of passage from then on up to term63,64.
In humans,  around 34 breast  cancer patients who have
been exposed to trastuzumab during pregnancy have been
described65. When trastuzumab was administered during the
second or third trimester,  the pregnancy was complicated
with  oligohydramnios,  resulting  in  preterm delivery  in  5
cases reported66. The remaining 29 cases became accidentally
pregnant  during trastuzumab treatment  with consequent
exposure  during  the  first  trimester66,67.  First-trimester
exposure was not associated with pregnancy complications or
fetal malformations, and no cases of oligohydramnios were
described66,67.
Therefore,  in  contrast  to  chemotherapy,  trastuzumab
exposure during the first trimester seems to be not associated
with congenital malformations, while exposure beyond the
second trimester is likely to produce “on-target” effects, with
a high number of cases developing oligohydramnios65. Thus,
elective administration of trastuzumab should be avoided
during pregnancy and postponed until after delivery11,25. No
cases of women treated with pertuzumab or T-DM1 during
pregnancy have been reported so far65, and only one case of
lapatinib exposure has been published68. Thus, these drugs
should not be used in pregnant patients65.
Endocrine therapy
In  women  with  BCP,  endocrine  therapy  is
contraindicated11,25.  Fetal  malformations  (i.e.,  craniofacial
malformations and ambiguous genitalia) have been described
in  children with  in  utero  exposure  to  tamoxifen70,71.  Hence,
the  use  of  endocrine  agents  should  be  postponed  until  after
delivery11,25,69.
Supportive care
Among 5-HT3 receptor antagonists, ondansetron was shown
to  be  not  associated  with  an  increased  risk  of  developing
adverse fetal outcomes74. Granisetron does not seem to cross
the  placenta75,  while  no  data  are  available  about  NK1
receptor  antagonists  and  palonosetron72,73.  Steroids  are
contraindicated during the first trimester because of the risk
of  cleft  palate,  while  they  can  be  administered  during  the
second  and  third  trimesters11,  with  a  preference  for
methylprednisolone  and  hydrocortisone,  which  are
extensively metabolized in the placenta and do not reach the
fetus11,76.
The safety of G-CSF during pregnancy is limited to a small
retrospective series77-79,59,  and they should be used only if
strictly indicated11,26.
Obstetric care
As  mentioned,  cytotoxic  chemotherapy  can  be  safely
administered  in  the  second  and  third  trimesters,  but  can  be
associated  with  an  increased  risk  of  obstetric  and  fetal
complications.  The  most  common  complication  associated
with  chemotherapy  exposure  is  intrauterine  growth
restriction,  with  an  incidence  of  7–9%  up  to  22%  in  the
largest  case  series45,80,81.  Other  possible  obstetric
complications,  including  premature  rupture  of  membranes,
can occur in 17–27% of cases45,80,81.
Pregnancy in cancer patients should be considered and
monitored  as  “high  risk”11,25.  A  multidisciplinary  team
should be involved in the care of women with BCP from the
earliest phase possible. An ultrasound confirming dates with
detailed fetal anatomic evaluation before treatment initiation
is recommended to rule out preexisting fetal  anomalies26.
During  treatment,  fetal  ultrasound  monitoring  is
recommended at regular intervals11, and the mother should
be  accurately  evaluated  at  each  chemotherapy  cycle,
including  assessment  of  arterial  blood  pressure  and
proteinuria.  The mode of  delivery should not differ  from
usual obstetric indications, and delivery should occur in a
tertiary center82. Furthermore, the placenta should be sent for
histological evaluation to assess possible breast cancer cell
contamination83.
Long-term outcomes of children after
in utero exposure to anticancer
therapies
Reassuring  data  about  the  long-term  follow-up  of  babies
born from mothers treated for cancer during pregnancy have
been  reported48.  With  an  observation  period  between  18
months  and  20  years,  the  children’s  general  health,  growth,
behavior,  and  hearing  did  not  differ  to  those  of  the  general
population;  moreover,  cardiac  dimensions  and  functions
were  within  normal  ranges48.  Cognitive  development  scores
were overall within normal ranges but lower for children who
were  born  preterm  than  for  those  born  at  full  term48.
Another  multicenter  case-control  study  confirmed  these
results49.  No  significant  difference  in  cognitive  development
was  observed  between  cases  and  controls;  however,  the
gestational  age  at  birth  was  correlated  with  the  cognitive
outcome in  both study groups,  confirming that  prematurity
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is correlated with a worse cognitive outcome independent of
cancer treatment49.
Preterm delivery can lead to several complications also in
the  general  population,  and  the  risk  of  occurrence  of
complications increases with decreasing gestational age at
birth84.  Thus,  delivery  after  37  weeks  of  gestation  is
recommended whenever possible,  and iatrogenic preterm
delivery should be avoided11,25. Although these findings are
encouraging, more data and longer follow-up are necessary
to identify possible adverse effects that may not be apparent
until later in life, including cardiac function impairment and
infertility85.
Conclusions
The  diagnosis  of  BCP  represents  a  unique  challenge  for  the
patient, her caregivers, and the treating physicians and often
raises several religious, moral, or social issues that should be
taken into account86.  The complex medical situation in BCP
requires  the  involvement  of  a  multidisciplinary  team  from
the early phases of its management11,25.
Current guidelines on this topic rely on limited evidence.
Hence, further research is required to obtain more conclusive
data.  Prospective studies  for  the management of  BCP are
ongoing in the US and Europe. Since running randomized
trials is impossible in this setting, the participation of patients
in  international  registries,  such  as  the  one  organized  in
Europe by the International Network on Cancer, Infertility
and Pregnancy (https://www.esgo.org/network/incip/), will
help  accrue  adequate  numbers  to  provide  more  robust
evidence on the management of women with BCP.
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